Arbutus Biopharma Corp Loss Contingency, Estimate of Possible Loss
Arbutus Biopharma Corp (ABUS) had Loss Contingency, Estimate of Possible Loss of $400.00 thousand as of 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Notes
us-gaap:LossContingencyEstimateOfPossibleLoss · last filed 2020-11-05
- 2020-09-30: Loss Contingency, Estimate of Possible Loss $400.00K.
- 2020-06-30: Loss Contingency, Estimate of Possible Loss $400.00K.
- 2020-03-31: Loss Contingency, Estimate of Possible Loss $400.00K.
| Period end | Loss Contingency, Estimate of Possible Loss |
|---|---|
| 2020-09-30 | $400.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $400.00K 10-Q · filed 2020-08-07 |
| 2020-03-31 | $400.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |